Macquarie Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Macquarie Group’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-70	Closed	-$7K	–	2311
2017 Q4	$7K	Buy	+70	New	+$7.89K	﹤0.01%	2334

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group's IMDX Position: Q1 2018 in Review

Macquarie Group sold out of Insight Molecular Diagnostics (IMDX) in Q1 2018, closing a stake of 70 shares — an estimated $7K sold.

Macquarie Group first reported a position in IMDX in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 39 funds tracked by Wall St. Rank hold IMDX as of Q1 2018.

Macquarie Group reported no remaining Insight Molecular Diagnostics position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 70 Insight Molecular Diagnostics shares in Q1 2018, an estimated $7K.
Macquarie Group first reported a position in Insight Molecular Diagnostics in Q4 2017 and held it in 1 quarter.
Macquarie Group's Insight Molecular Diagnostics position peaked at $7K in Q4 2017.
39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.